Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial

Annals of Internal Medicine

Volumn 132, Issue 11, 2000, Pages 871-879

  Seibold, James R ^a   Korn, Joseph H ^b   Simms, Robert ^b   Clements, Phillip J ^c   Moreland, Larry W ^d   Mayes, Maureen D ^e   Furst, Daniel E ^f   Rothfield, Naomi ^g   Steen, Virginia ^h   Weisman, Michael ⁱ   Collier, David ^j   Wigley, Fredrick M ^k   Merkel, Peter A ^b   Csuka, Mary Ellen ^l   Hsu, Vivien ^a   Rocco, Susan ^m   Erikson, Mark ^m   Hannigan, John ^m   Harkonen, W Scott ^m   Sanders, Martin E ^m  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d The University of Alabama at Birmingham   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f BENAROYA RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^h GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^l MEDICAL COLLEGE OF WISCONSIN   (United States)

^m Bradley Pharmaceuticals Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT RELAXIN;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBROSIS; FORCED EXPIRATORY VOLUME; HAND MOVEMENT; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; METRORRHAGIA; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA; SCORING SYSTEM; SKIN;

EID: 0034612234     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-11-200006060-00004     Document Type: Article

References (31)

1. Steinetz BG, Schwabe LC, Weiss G, eds. Relaxin: Structure, Function and Evolution. New York: New York Academy of Sciences; 1982:1-246.
2. Bryant-Greenwood GD, Schwabe C. Human relaxins: chemistry and biology Endocr Rev. 1994;15:5-26.
3. Sherwood OD. Relaxin. In: Knobil E, Neill JD, eds. The Physiology of Reproduction. New York: Raven Pr; 1988:585-673.
4. Unemori EN, Bauer EA, Amento EP. Relaxin alone and in conjunction with interferon-gamma decreases collagen synthesis by cultured human scleroderma fibroblasts. J Invest Dermatol. 1992;99:337-42.
5. Unemori EN, Amento EP. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J Biol Chem. 1990; 265:10681-5.
6. Unemori EN, Pickford LB, Saltes AL, Piercy CE, Grove BH, Erikson ME, et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest. 1996;98:2739-45.
7. Unemori EN, Beck LS, Lee WP, Xu Y, Siegel M, Keller G, et al. Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J Invest Dermatol. 1993;101:280-5.
8. Seibold JR. Scleroderma In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. 5th ed. Philadelphia: WB Saunders; 1997:1133-62.
9. Seibold JR, Clements PJ, Furst DE. Treatment of systemic sclerosis by disease-modifying agents. In: Clements PJ, Furst DE, eds. Systemic Sclerosis Baltimore: Williams & Wilkins; 1996:535-48.
10. Casten G, Boucek RJ. Use of relaxin in the treatment of scleroderma. JAMA. 1958;166:319-24.
11. Seibold JR, Clements PJ, Furst DE, Mayes MD, McCloskey DA, Moreland LW, et al. Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis. J Rheumatol. 1998;25:302-7.
12. Seibold JR, McCloskey DA, Clements PJ, Mayes MD, Rocco SE, Harkonen WS, et al. Six month pilot trial of recombinant human relaxin (rhRlx) in diffuse scleroderma (DS) [Abstract]. Br J Rheumatol. 1997;36(Suppl 1):29.
13. Vandlen R, Winslow J, Moffat B, Rinderknecht E. Human relaxin purification, characterization and production of recombinant relaxins for structure function studies. In: MacLennan AH, Tregear GW, Bryant-Greenwood GD, eds. Progress in Relaxin Research. River Edge, NJ: Global Publications Services; 1995:59-72.
14. Efron B. Forcing a sequential endpoint to be balanced. Biometrika. 1971;58: 403-17.
15. Efron B. Randomizing and balancing a complicated sequential experiment. In: Miller RG Jr, Efron B, Brown BW Jr, Moses LE, eds. Biostatistics Casebook. New York: J Wiley; 1980:19-30.
16. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 1999;42:1194-203.
17. Clements PJ, Furst DE, Seibold JR, Lachenbruch PA. Controlled trials: trial design issues. In: Clements PJ, Furst DE, eds. Systemic Sclerosis. Baltimore. Williams & Wilkins; 1995:515-33.
18. Pope JE, Baron M, Bellamy N, Campbell J, Carette S, Chalmers I, et al. Variability of skin scores and clinical measurements in scleroderma. J Rheumatol. 1995;22:1271-6.
19. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993;20:1892-6.
20. Clements PJ, Lachenbruch PA, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281-5.
21. Furst DE, Clements PJ, Steen VD, Medsger TA, Masi AT, D'Angelo WA, et al. The modified Rodran skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol. 1993;25:84-8.
22. Fries JP, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9:789-93.
23. Unemori EN, Erikson ME, Rocco SE, Sutherland KM, Parsell DA, Mak J, et al. Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women. Hum Reprod. 1999;14:800-6.
24. Akesson A. Cyclophosphamide therapy for scleroderma. Curr Opin Rheumatol. 1998;10:579-83.
25. White B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn JH, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum. 1995;38:351-60.
26. Seibold JR, McCloskey DA. Skin involvement as a relevant outcome measure in clinical trials of systemic sclerosis. Curr Opin Rheumatol. 1997;9: 571-5.
27. Seibold JR, Furst DE, Clements PJ. Why everything (or nothing) seems to work in the treatment of scleroderma. J Rheumatol. 1992;19:673-6.
28. Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum. 1990; 33:1256-63.
29. Black CM. Measurement of skin involvement in scleroderma. J Rheumatol. 1995;22:1217-9.
30. Steen VD, Conte C, Owens GR, Medsger TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37:1283-9.
31. Remy-Jardin M, Remy J, Wallaert B, Bataille D, Hatron PY. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology 1993;188: 499-506.